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In the last two decades, there have been major advances in
our understanding of the thyroid physiology during preg-
nancy, the role of thyroid hormones in fetal development,
and the eﬀects of thyroid dysfunction on pregnancy out-
comes. The main objective of this special issue was to high-
light how these advances have enhanced our knowledge and
inﬂuenced the clinical practice in the ﬁeld.
The emerging evidence for an association between thyr-
oid autoimmunity and spontaneous miscarriages is one of
such advances. As A. Stagnaro-Green reviews in this special
issue, since the publication of the ﬁrst report describing
the association in 1990 [1], many subsequent studies have
lent further evidence to support this association. However,
despite the robust evidence for the association, the patho-
genesis of miscarriages in pregnant women with thyroid
autoimmunity remains uncertain, and whether levothyrox-
ine treatment prevents the adverse outcome in these women
is yet to be conﬁrmed.
For many decades, it has been recognised that overt
maternal hypothyroidism during pregnancy is associated
with impaired neurological development of the oﬀspring;
however, several studies in the recent years have suggested
that even mild maternal thyroid hormone deﬁciency (subcli-
nical hypothyroidism and isolated maternal hypothyroxi-
naemia) during pregnancy can aﬀect the oﬀspring’s neuro-
psychological development [2, 3]. However, this association
has not been consistent in all studies [4], and J. Chevrier and
colleagues in this special issue report a prospective study
showing lack of association between maternal thyroid hor-
mone levelsat27-week gestation and neuropsychological de-
velopment of the oﬀspring. Indeed, as M. Moleti and coll-
eagues highlight in their review, there is also a great deal of
controversy surrounding the diagnosis, adverse eﬀects, and
managementofisolatedmaternalhypothyroxinaemiainpre-
gnancy, and more studies are needed to resolve these con-
troversies.
The last two decades have also witnessed signiﬁcant ad-
vances in the diagnosis and management of hypothyroidism
in pregnancy. The importance of trimester-speciﬁc reference
ranges for thyroid function tests in pregnancy has been
established[5,6];ithasbecomeclearthattheupperreference
limit of serum thyrotropin (TSH) in pregnancy is much low-
er than that in the general population. It has also been con-
vincingly shown that most hypothyroid women need an
increased dose of levothyroxine during pregnancy. How-
ever, there remains uncertainty at what level of TSH should
the levothyroxine replacement be considered and whether
women with isolated maternal hypothyroxinaemia or iso-
lated positive thyroid peroxidase antibodies should be treat-
ed with levothyroxine. Furthermore, there is no consensus
on whether all pregnant women should be screened for
hypothyroidism. J. Klubo-Gwiezdzinska and colleagues re-
view the issues surrounding indications, eﬃcacy, and mon-
itoring of levothyroxine replacement in pregnancy, and J.
H. Lazarus appraises evidences for and against screening
all pregnant women for thyroid dysfunction. The current
guidelines from the Endocrine Society and the American
Thyroid Association do not endorse universal screening of
pregnant women for thyroid dysfunction but recommend
case-ﬁnding approach in high-risk pregnant women [5, 6].
However, V. Nambiar and colleagues show, in the Asian-
Indian population, that the case-ﬁnding approach misses
a signiﬁcant proportion of pregnant women with thyroid
dysfunction, in line with ﬁndings of several studies from2 Journal of Thyroid Research
the western countries. Their study also provides further
evidence to support that both maternal thyroid autoim-
munity and maternal mild hypothyroidism are associated
with an increased risk of spontaneous miscarriages. And,
although not as ﬁercely debated as screening pregnant
women for hypothyroidism, there is also lack of consensus
on screening for postpartum thyroiditis. M. A. Adlan and
L. D. Premawardhana review the issues surrounding screen-
ing for postpartum thyroiditis and the utility of thyroid
peroxidase antibodies testing as a screening tool for this
condition.
In pregnancy, Graves’ disease is the commonest cause of
hyperthyroidism, and thionamide antithyroid drugs are the
mainstay of treatment for this condition. However, in the
recent years, reports of rare association of carbimazole (and
its active metabolite, methimazole) use in early pregnancy
with multiple congenital malformations in the foetus and
association of propylthiouracil with severe liver injury have
led to the controversy surrounding the choice of antithyroid
drugs in pregnancy. For example, which antithyroid drug
should be prescribed for a woman with Graves’ disease
planning pregnancy? If a pregnant woman is on propylth-
iouracil, should the drug be switched to carbimazole (or
methimazole) after the ﬁrst trimester? In this special issue, P.
Bowman and B. Vaidya, by analysing all birth defects related
to maternal treatment of carbimazole and propylthiouracil
reported to the UK Pharmacovigilance authority over a 47-
year period, provide further evidence to support an em-
bryopathy associated with carbimazole exposure in utero.
However, their study also raises a question whether the
currently apparent lack of association of similar embry-
opathy with propylthiouracil is related to historically lower
use of the drug as compared to carbimazole or methima-
zole. Furthermore, transient gestational hyperthyroidism—
another common cause of hyperthyroidism in pregnancy—
is often confused with Graves’ disease, sometimes leading
to inappropriate treatment. A. M. Goldman and J. H.
Mestman review the aetiology, pathogenesis, diagnosis, and
management of this intriguing condition.
The association between severe iodine deﬁciency and
cretinism has been known for more than a century [7].
Furthermore, recent studies have shown that mild iodine
deﬁciency is also associated with impaired cognitive and
behaviour outcomes in the children, including attention
deﬁcit hyperactivity disorder. Despite these observations and
all national and international eﬀorts to optimise dietary
iodine intake in the population, iodine deﬁciency during
pregnancycontinuestobeamajorpreventablecauseofmen-
tal retardation in many countries. In fact, recent studies sug-
gest that iodine deﬁciency is on the rise in Europe, Australia,
and the USA [8–10]. C. Yarrington and E. N. Pearce review
the adverse eﬀects of dietary iodine deﬁciency on maternal
thyroidfunctionandfetalneurologicaloutcomesanddiscuss
the recommendations for optimum dietary iodine intake
during pregnancy.
As a byproduct of a modern life, humans are increasingly
being exposed to environmental endocrine disrupting chem-
icals, with potential harmful health consequences. Recent
studies suggest that some of these chemicals could interfere
with normal thyroid hormone function. Therefore, there
is a growing concern that an exposure to these chemicals
during pregnancy may adversely aﬀect maternal and fetal
thyroid function impacting on the fetal development, as M.-
L. Hartoft-Nielsen and colleagues discuss in their review.
Finally,althoughfortunatelyrare,thyroidcancerpresents
specialchallengesinthemanagementduringpregnancy.S.A.
Imran and M. Rajaraman discuss various issues surrounding
management of diﬀerentiated thyroid cancer in pregnancy
and underline the importance of multidisciplinary approach
in the management. However, much of the clinical decisions
in the management of thyroid cancer in pregnancy are
hampered by the lack of good quality evidence, as G. V. Alves
and colleagues highlight in their systemic review.
We believe that the papers in this special issue illustrate
the highlights of advances made in the diverse areas of
thyroid and pregnancy over the last two decades. At the same
time, they also underline many yet unanswered questions
and areas for further studies. However, with the volume and
the quality of ongoing research activities in the ﬁeld, we are
optimistic that we will not need to wait for a further two
decades to have the answers for many of these questions.
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